University of North Carolina, Chapel Hill: Autistic Disorder trials

The registry lists 10 Autistic Disorder studies with University of North Carolina, Chapel Hill as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 5Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sulforaphane for the Treatment of Young Men With Autism Spectrum DisorderCompletedNCT02909959Phase 2Results posted
• Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and AdolescentsCompletedNCT01731119Phase 2Results posted
• A Study of Oxytocin in Children and Adolescents With Autistic DisorderCompletedNCT01308749Phase 2Results posted
• FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum DisordersCompletedNCT01028820Phase 4Results posted
• Study of Aripiprazole to Treat Children and Adolescents With AutismCompletedNCT00619190Phase 2Results posted
• Early Intervention With Fluoxetine in AutismCompletedNCT00183339Phase 2Results posted
• Social Cognition and Interaction Training for AutismCompletedNCT02382172Not applicable
• Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine TreatmentWithdrawnNCT02353130
• Brain Imaging of Intranasal Oxytocin Treatment in AutismCompletedNCT01945957Phase 1
• Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum DisordersCompletedNCT00609531Phase 1